Risk factors for recurrent wheezing after bronchiolitis in infants: 2-year follow up in China

Sainan Chen
Children's Hospital of Soochow university

Wenjing Gu
children's hospital of soochow university

Min Wu
children's hospital of soochow university

Chuangli Hao
children's hospital of soochow university

Canhong Zhu
children's hospital of soochow university

Xuejun Shao
children's hospital of soochow university

Yuqing Wang
Children's Hospital of Soochow University

Keywords: bronchiolitis, eczema, recurrent wheezing

DOI: https://doi.org/10.21203/rs.3.rs-26354/v3

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Infants with bronchiolitis have an increased risk of developing recurrent wheezing and asthma. However, the risk factors for the development of recurrent wheezing after bronchiolitis remains controversial.

Objective: To investigate the incidence of post-bronchiolitis recurrent wheezing and associated risk factors.

Methods: Infants with bronchiolitis were enrolled from November 2016 through March 2017. Nasopharyngeal aspirates were obtained for detection of respiratory viruses which were analyzed by reverse transcriptase polymerase chain reaction (RT-PCR) and direct immunofluorescent assay. Serum cytokines including TSLP, IL2, IL13, TIMP-1, MMP-9, IL33, IL5, IL4, IL25, TNF-α and MIP-1α were measured by flow cytometry. Patients were followed every 3 months for a duration of 2 years by telephone or at outpatient appointments.

Results: We enrolled 89 infants, of which 81 patients were successfully followed up. In total, 22.2% of patients experienced recurrent wheezing episodes. The proportion of patients with history of eczema, systemic glucocorticoid use and patients with moderate-to-severe disease were significantly higher in the recurrent wheezing group than the non-recurrent wheezing group (83.3% vs 52.4%; 66.7% vs 36.5%; 61.1% vs 33.3%, respectively, all P<0.05); There were no significant differences between patients with and without recurrent wheezing episodes in the levels of TSLP, IL2, IL13, TIMP-1, MMP-9, IL33, IL5, IL4, IL25, TNF-α and MIP-1α (P>0.05). Logistic regression analysis showed that history of eczema was an independent risk factor for post-bronchiolitis recurrent wheezing (odds ratio [OR]=5.622; 95% confidence interval [CI], 1.3–24.9; P=0.023).

Conclusion: The incidence of recurrent wheezing among infants after contracting bronchiolitis was 22.2% during a 2-year follow-up. History of eczema was the only independent risk factor identified and no correlation was found between the specific virus and disease severity in children with post-bronchiolitis recurrent wheezing.

Introduction

Acute bronchiolitis is a common lower respiratory tract disease characterized by inflammation of the bronchioles with a diameter of 75–300 μm. It is often caused by viral infection in infants under two years and symptoms include wheezing, cough, tachypnea and chest retractions. Respiratory syncytial virus (RSV) is the most common cause of acute bronchiolitis among infants[1, 2].

Recurrent wheezing is sometimes observed after acute bronchiolitis attacks[3]. Follow up data from abroad showed that the incidence of post-bronchiolitis recurrent wheezing is as high as 31%[4] and about 48% of patients were diagnosed with asthma at the age of 7 years old following severe RSV bronchiolitis [5]. In a follow-up study in China[6], 35.1% (26/74) of infants at 6 months of age or less with bronchiolitis...
had recurrent wheezing by the age of 3 years. However, the mechanism of recurrent wheezing after bronchiolitis has not been elucidated, and knowledge around risk factors is still controversial.

Current research suggests that risk factors for post-bronchiolitis recurrent wheezing are as follows: allergy\(^7\), the elevation of specific IgE level\(^8\), family history of asthma\(^9\), passive smoking\(^10\), disease severity\(^11\) and others. A large number of epidemiological and prospective studies showed that respiratory syncytial virus infection is a risk factor for recurrent wheezing or asthma after bronchiolitis\(^5, 12, 13\). Some researchers believe that rhinovirus is a more important factor for recurrent wheezing\(^14\). In addition, bocavirus and metapneumovirus are also associated with recurrent wheezing and asthma following bronchiolitis\(^13, 15\). However, Bacharier et al showed that post-bronchiolitis recurrent wheezing has no relation to viral pathogens\(^5\). In recent years, increasing attention has been paid to the relationship between cytokine level and post-bronchiolitis recurrent wheezing. One study showed that IL-3 can be used as a predictor of recurrent wheezing after bronchiolitis\(^16\), and some researchers believe that MIP-1\(\alpha\) can be used as a biomarker to predict recurrent wheezing\(^17\). However, no accurate biomarkers for the prediction of recurrent wheezing are currently available for infants with bronchiolitis.

It is of great significance for treatment and prevention to understand the risk factors for recurrent wheezing following bronchiolitis. However, there are few follow-up studies of bronchiolitis in China, and the risk factors for recurrent wheezing remain unclear. Therefore, the objective of this study was to identify potential predicting factors for post-bronchiolitis recurrent wheezing in infants through a two-year follow-up study.

**Methods**

Infants diagnosed with bronchiolitis and hospitalized at the Department of Respiratory Disease at Children’s Hospital Soochow University, China, from November 2016 through March 2017, were enrolled in this study. Nasopharyngeal aspirates were obtained for detecting respiratory virus and analyzed by reverse-transcriptase polymerase chain reaction (RT-PCR) and direct immunofluorescent assay. Serum cytokines including TSLP, IL2, IL13, TIMP-1, MMP-9, IL33, IL5, IL4, IL25, TNF-\(\alpha\) and MIP-1\(\alpha\) were measured by flow cytometry. The patients were followed every 3 months for a duration of 2 years by telephone or at outpatient appointments.

Recurrent wheezing was defined as two or more episodes following initial bronchiolitis for two years. The study was approved by the ethics committee of the Children’s Hospital Soochow University (Approval No.:2016050). Informed consent was obtained from the parents of all children enrolled in this study.

Inclusion criteria: 1) Age: 1–24 months; 2) Patients were hospitalized with bronchiolitis; 3) Bronchiolitis was defined as the first wheezing episode characterized by cough, tachypnea and chest retractions.

Exclusion criteria: Neuromuscular disease, congenital airway deformity, congenital heart disease, gastroesophageal reflux disease, bronchial foreign body inhalation, primary or secondary immune
deficiency or other immune-associated diseases were excluded.

Disease severity criteria: according to Wang expiratory flow limitation (EFL) scoring\textsuperscript{[18]}, the severity of disease was graded as follows (Table 1): 0–4.9 was mild; 5–8.9 was moderate; 9–12 was severe.

**Sample collection**

Nasopharyngeal aspirates were obtained using a suction catheter passed through the nose into the lower part of the pharynx for detection of viruses. Peripheral venous blood (2 ml) was also collected for detection of blood routine, humoral and cellular immunity and cytokines.

**Detection of seven common viruses by direct immunofluorescent assay (DFA)**

DFA was used to detect respiratory syncytial virus (RSV), influenza virus A (IVA), influenza virus B (IVB), parainfluenza virus (PIV) I, PIV II, PIV III, and adenovirus (ADV). All assay kits were purchased from Chemicon (USA) and all staining procedures were performed according to the manufacturer’s instructions. Immunostained preparations were viewed with a fluorescence microscope (Leica 020-518.500, Germany).

**Detection of the metapneumovirus (hMPV), rhinovirus (hRV), bocavirus (hBoV) gene by real-time polymerase chain reaction (RT-PCR)**

For hMPV detection, primers were designed to specifically amplify the N gene (213 base pairs [bps]). The forward and reverse primers were hMPV-F:5’-AACCGTGTAATGATGCACTC-3’ and hMPV-R:5’-CATTGGTGGACGGGCCCATAA-3’, respectively. The cyclic temperature settings were 94 °C, 30 s; 55 °C, 30 s; 68 °C, 30 s; amplified by 45 cycles with the last at 68 °C for 7 min.

For hRV detection, the primers and probe sequences were HRV-F: 5’-TGGACAGGGTGAGAGC-3′;HRV-R:5’-CAAAGTAGTGTCCGTCATCC-3′;HRV-probe:FAM-TCCTCCGCCCCTGA ATG-TAMRA. The cyclic temperature settings were 94°C, 30 s; 56°C, 30 s; 72°C, 30 s; amplified, 40 cycles.

For hBoV detection, the primers and probe sequences were HBoV-F:5’-TGACATTCAACTACCAACAACCTG-3′;HBoV-R:5’CAGATCCTTTTCCCTCCTCAATAC-3’; HBoV-probe: FAMAGCACCACAAACACCTCAGGGG-TAMRA. The cyclic temperature settings were 94°C,30 s; 56°C, 30 s; 72°C, 30 s; amplified for 40 cycles.

**Routine blood test**

Peripheral venous blood (2 ml) was collected and anticoagulated with EDTA from every patient. The blood was tested by an automatic five classification hematology analyzer for white blood cell count, absolute neutrophil count, absolute lymphocyte count and absolute count of eosinophils.

**Testing of humoral immunity**
Detection indices: IgG, IgM and IgA. IgG and IgM were determined by transmission immunoassay, and IgA was determined by immunoturbidimetry.

**Testing of cellular immunity**

Peripheral venous blood (2 ml) was collected on EDTA anticoagulant. Flow cytometry of Beckman Coulter company was used for analysis. The kit was purchased from Immunotech (France). Detection indices: CD3+, CD3+ CD4+, CD4+ / CD8+, CD3+CD8+, CD19+CD23+, CD3-CD16+CD56+ and CD3-CD19+.

**Detection of serum levels of cytokine**

The peripheral blood was centrifuged at 2500r/min for 5 minutes. Supernatants were frozen at -80°C. Serum levels of cytokines (TNF-α, IL-2, IL-13, IL-4, IL-5, IL-25, IL-33, TSLP, TIMP-1, MMP-9 and MIP-1α) were measured by flow cytometry. Flow cytometry (Beckman Coulter, Brea, CA, USA) was performed according to the manufacturer’s instructions (Immunotech, Marseille, France). All assay kits were purchased from BEIJING TONGSHENG SHIDAI BIOTECH CO., LTD. Data were automatically processed and analyzed using FCAP Array 3.0 with the standard curve produced from the cytokine standard.

**Data collection**

Each patient’s data, including age, gender, gestational age at delivery, birth weight, feeding patterns, history of eczema, family history of asthma, exposure to smoking, and pet contact were recorded.

**Follow-up of patients**

After discharge from hospital, the patients were followed up every 3 months for a 2-year period by outpatient visits or telephone consultations.

**Statistical analysis**

SPSS version 18.0 software was used for data analysis. Distribution normality of continuous data was tested by the P-P plots methods before comparison. Data with normal distribution were represented as mean ± standard deviation (SD) and analyzed by t tests. Continuous data with non-normal distribution were represented as median (minimum-maximum) and analyzed with the Mann-Whitney U test. Categorical data were represented as frequency and analyzed with Chi square examination. Predictors of recurrent wheezing were analyzed using a stepwise logistic regression model.

**Results**

1. **Recruitment and general characteristics**

The study included 89 cases (56 males and 33 females; mean age: 4.68±4.37months).

2. **Viral detection rate in clinical specimens**
The detection rate for respiratory viruses was 50.6%. The most common pathogen was RSV (44.4%), followed by HRV (3.7%) and HBoV (2.5%). Two patients (2.5%) had co-infections with RSV and HRV.

3. Follow-up results

A total of 81 patients were successfully followed up and eight patients were lost to follow up due to the wrong telephone number being recorded. Of the 81 infants whose parents answered the telephone interview every three months, 22 (27.2%) infants experienced one single episode and 18 (22.2%) infants experienced recurrent wheezing, including 3(3.7%) with 2 episodes, 15 (18.5%) with ≥ 3 episodes. (Figure 1).

Baseline data between patients with and without recurrent wheezing episodes

History of eczema was more common in patients with recurrent wheezing episodes ($P=0.037$, continuity correction). There were no significant differences between patients with and without recurrent wheezing episodes with regards to sex, age, premature birth, feeding patterns, family history of asthma and others ($P>0.05$) (Table 3).

Clinical characteristics between patients with and without recurrent wheezing episodes

There were no significant differences between patients with and without recurrent wheezing episodes with regards to fever, feeding difficulty, chest retractions and other clinical characteristics ($P>0.05$); however, the proportion of patients with moderate to severe conditions in the recurrent wheezing group was higher than that in patients without recurrent wheezing ($P=0.033$) (Table 4).

Treatment and course of disease between patients with and without recurrent wheezing episodes

Systemic glucocorticoid treatment was higher in patients with recurrent wheezing episodes than those without wheezing episodes ($P=0.031$, continuity correction). There were no significant differences in the need for oxygen treatment, length of hospital stay and the length of illness between children with and without recurrent wheezing episodes ($P>0.05$) (Table 5).

Laboratory examinations between patients with and without recurrent wheezing episodes

There were no significant differences between patients with and without recurrent wheezing episodes in blood cell count, humoral immunity, cellular immunity, serum total Ig E and antigen-specific Ig E ($P>0.05$) (Table 6).

Serum cytokines in patients with and without recurrent wheezing episodes

There were no significant differences between patients with and without recurrent wheezing episodes in the levels of TSLP, IL2, IL13, TIMP-1, MMP-9, IL33, IL5, IL4, IL25, TNF-α and MIP-1α ($P>0.05$) (Table 7).

Analysis of risk factors of recurrent wheezing after bronchiolitis
We used single factor analysis to evaluate the statistically significant or near significant variables (history of eczema, systemic glucocorticoid treatment, moderate to severe condition, IL-25). By logistic multivariable regression analysis, history of eczema was identified as potential risk factor for recurrent wheezing with an OR (95% CI) of 5.622 (1.3,24.9); P <0.05 (Table 8).

Discussion

In this study, 49.4% of the infants had at least one wheezing episode, and 22.2% of infants had experienced recurrent wheezing during the 2-year follow-up period. Several previous studies reported that the incidence of recurrent wheezing in infants with bronchiolitis was about 16–60%.[3-6,17,19-22] Zhang X et al.[6] followed up 74 Chinese infants who were hospitalized for bronchiolitis until the age of 3 years and found that 35.1% of the infants had recurrent wheezing. Another 1.5-year follow-up study[20] showed the prevalence of post-bronchiolitis recurrent wheezing among infants was 19.4%. In previous studies, allergy, antigen-specific IgE, family history of asthma, exposure to smoking, severity of disease and specific pathogens or serum level of cytokines were found to be risk factors for recurrent wheezing[7,9-11,13].

Asthmatic diseases often occur in individuals with allergic or atopic constitution, and allergic diseases may have similar pathogenesis[23]. Children with allergic constitution are more susceptible to severe RSV infection and have a higher risk of developing airway hyperresponsiveness[24]. In a case-control study[7], it was found that 48% of children had recurrent wheezing, and allergic constitution was considered to be a risk factor. It has been reported that allergy has the strongest correlation with eczema before the age of 1 year old[25]. Several studies have shown that recurrent wheezing in infants is related to allergic dermatitis (eczema)[26,27]. Dumas et al.[28] analyzed the prospective data of 921 hospitalized children with bronchiolitis in 17 centers in the United States, and found that the risk of recurrent wheezing was significantly increased in children with eczema. It has been confirmed that eosinophils play a key role in the pathogenesis and development of atopic diseases including asthma and eczema[29,30]. Accordingly, one study[31] reported that recurrent wheezing at 36 months after bronchiolitis in infants was associated with eosinophilia. In our study, the proportion of infants with history of eczema in the recurrent wheezing group was 83.3%, which was significantly higher than in the non-recurrent wheezing group. Multivariate regression analysis suggested that history of eczema was the only independent risk factor for recurrent wheezing post bronchiolitis. Therefore, it is suggested that early intervention should be carried out in infants with bronchiolitis accompanied by eczema in order to reduce the incidence of recurrent wheezing.

Several prior studies have reported that RSV infection in early life may have a profound impact on the development of recurrent wheezing and/or asthma[5,13,32]. Other studies demonstrated that hRV-related bronchiolitis may be associated with an increased prevalence of recurrent wheezing and asthma in later childhood[9,33]. However, studies by teeratakulpisan et al.[19] and Valkonen et al.[34] found no consistent relationship between the type of virus and recurrent wheezing. In our study, 44.4% of infants were infected with RSV and 3.7% were infected with hRV. The RSV rate was lower with respect to the above studies which may be related to the test method (DFA) being associated with variable and lower sensitivity
compared with PCR. We found there was no significant difference in terms of the causative virus and recurrent wheezing after bronchiolitis. As such, we suggest that further study is required to ascertain whether type of virus can be used as a predictor of recurrent wheezing.

Two demographically and clinically important differences were observed in our study between the two groups, namely, the percentage of infants with moderate to severe bronchiolitis and the usage of systemic glucocorticoids were significantly higher in infants with recurrent wheezing. A longitudinal study [11] found that in 343 children with bronchiolitis caused by RSV, the severity of the disease could be used as a predictor of asthma and atopic diseases. In addition, a 7-year follow-up study [35] showed that prednisolone could reduce recurrent wheezing after the first rhinovirus infection while another study [36] showed that dexamethasone could not reduce post-bronchiolitis recurrent wheezing 1 year later. Our study did not find that severe bronchiolitis or the usage of systemic glucocorticoids was a risk factor for recurrent wheezing, which is different from other studies. This may be related to the small sample size and/or the inclusion of less severe cases.

The pathogenesis of bronchiolitis is mainly related to excessive type 2 and/or deficient type 1 immune responses [37]. Plasma level of TNF-a, which originates from Th1 cytokine, has been reported to be of great significance in predicting the development of recurrent wheezing during acute bronchiolitis [38]. The serum level of IL-3, IL-4, IL-10, and IL-13, which originate from Th2 cytokine, were higher in children with RSV bronchiolitis secondary wheezing, and IL-3 can be used as a predictor of recurrent wheezing [16]. In our study, multivariate regression analysis showed that there was no significant difference in serum cytokine levels between patients with and without recurrent wheezing episodes. This may be related to the fact that we tested serum samples rather than nasopharynx aspirates.

In conclusion, the current study indicates the following conclusions: 1. the incidence of recurrent wheezing among infants after bronchiolitis was 22.2% across a 2-year follow-up; 2. history of eczema is a significant risk factor for post-bronchiolitis recurrent wheezing; 3. no correlation was found between the specific virus and disease severity in children with post-bronchiolitis recurrent wheezing.

Our study has some limitations. Firstly, the sample size was small, and the follow-up time was relatively short. Secondly, we could not confirm whether parents gave reliable information in the phone interview. Thirdly, pathogen detection was not performed for every wheezing attack following bronchiolitis. Lastly, immunofluorescence assays have variable and lower sensitivity compared with PCR which may lead to a lower virus detection rate.

**Abbreviations**

OR, odds ratio; CI, confidence interval; RSV, respiratory syncytial virus; IVA, influenza virus A; IVB, influenza virus B; PIV, parainfluenza virus; ADV, adenovirus; hMPV, metapneumovirus; hRV, human rhinovirus; hBoV, human bocavirus; SD, standard deviation; RW, recurrent wheezing.
Declarations

Acknowledgments

Not Applicable.

Authors’ contributions

YW designed the study. SC, MW performed the experiments. CZ and CH provided the statistical analysis. XS were responsible genomic analysis. SC, MW drafted the initial manuscript. WG and YW revised the manuscript, and all authors approved the final content of this manuscript.

Funding

This work was supported by the National Natural Science Foundation of China, No.81573167; No.81900012; Science and Technology Project of Jiangsu, No. BE2017657; Science and Technology Project of Suzhou, No. SYSD2017092; No. LCZX201809

Availability of data and materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate

All the participants’ parents or guardians gave their written informed consent for participation in the study. The study was approved by the ethics committee of Soochow University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests

Author details

a Department of Respiration, Children's Hospital of Soochow University, No.303 Jing De Road, Suzhou 215003, China.

b Department of Clinical laboratory, Children's Hospital of Soochow University, Suzhou 215003, China.

References
1. Robledo-Aceves M, Moreno-Peregrina MJ, Velarde-Rivera F, Ascencio-Esparza E. **Risk factors for severe bronchiolitis caused by respiratory virus infections among Mexican children in an emergency department.** *Medicine* 2018; 97(9):e0057.

2. Cui DW, Feng LZ, Chen Y, Lai SJ, Zhang ZK, Yu F, et al. **Clinical and Epidemiologic Characteristics of Hospitalized Patients with Laboratory-Confirmed Respiratory Syncytial Virus Infection in Eastern China between 2009 and 2013: A Retrospective Study.** *PloS one* 2016; 11(11).

3. Rinawi F, Kassis I, Tamir R, Kugelman A, Srugo I, Miron D. **Bronchiolitis in young infants: is it a risk factor for recurrent wheezing in childhood?** *World journal of pediatrics : WJP* 2017; 13(1):41-48.

4. Mansbach JM, Luna PN, Shaw CA, Hasegawa K, Petrosino JF, Piedra PA, et al. **Increased Moraxella and Streptococcus species abundance after severe bronchiolitis is associated with recurrent wheezing.** *The Journal of allergy and clinical immunology* 2020; 145(2):518-527 e518.

5. Bacharier LB, Cohen R, Schweiger T, Yin-Declue H, Christie C, Zheng J, et al. **Determinants of asthma after severe respiratory syncytial virus bronchiolitis.** *The Journal of allergy and clinical immunology* 2012; 130(1):91-100 e103.

6. Zhang X, Zhang X, Zhang N, Wang X, Sun L, Chen N, et al. **Airway microbiome, host immune response and recurrent wheezing in infants with severe respiratory syncytial virus bronchiolitis.** *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology* 2019.

7. de Sousa RB, Medeiros D, Sarinho E, Rizzo JA, Silva AR, Bianca AC. **Risk factors for recurrent wheezing in infants: a case-control study.** *Revista de saude publica* 2016; 50:15.

8. Sarria EE, Rita M, Weiguo Y, Valentina C, Tiller CJ, Jeffrey K, et al. **Atopy, cytokine production, and airway reactivity as predictors of pre-school asthma and airway responsiveness.** 2014; 49(2):132-139.

9. Midulla F, Pierangeli A, Cangiano G, Bonci E, Salvadei S, Scagnolari C, et al. **Rhinovirus bronchiolitis and recurrent wheezing: 1-year follow-up.** *The European respiratory journal* 2012; 39(2):396-402.

10. Nicolai A, Frassanito A, Nenna R, Cangiano G, Petrarca L, Papoff P, et al. **Risk Factors for Virus-induced Acute Respiratory Tract Infections in Children Younger Than 3 Years and Recurrent Wheezing at 36 Months Follow-Up After Discharge.** *The Pediatric infectious disease journal* 2017; 36(2):179-183.

11. Lu S, Hartert TV, Everard ML, Giezek H, Nelsen L, Mehta A, et al. **Predictors of asthma following severe respiratory syncytial virus (RSV) bronchiolitis in early childhood.** 2016; 51(12):1382-1392.

12. Fauroux B, Simoes EAF, Checchia PA, Paes B, Figueras-Aloy J, Manzoni P, et al. **The Burden and Long-term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early Childhood.** *Infect Dis Ther* 2017; 6(2):173-197.

13. Escobar GJ, Masaquel AS, Li SX, Walsh EM, Kipnis P. **Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancy.** *BMC pediatrics* 2013; 13:97.
14. Koponen P, Helminen M, Paassilta M, Luukkaala T, Korppi M, European Respiratory Journal. *Preschool asthma after bronchiolitis in infancy*. 2012; 39(1):76-80.

15. Zomer-Kooijker K, van der Ent CK, Ermers MJ, Uiterwaal CS, Rovers MM, Bont LJ, et al. *Increased risk of wheeze and decreased lung function after respiratory syncytial virus infection*. *PloS one* 2014; 9(1):e87162.

16. Bertrand P, Lay MK, Piedimonte G, Brockmann PE, Palavecino CE, Hernandez J, et al. *Elevated IL-3 and IL-12p40 levels in the lower airway of infants with RSV-induced bronchiolitis correlate with recurrent wheezing*. *Cytokine* 2015; 76(2):417-423.

17. Sugai K, Kimura H, Miyaji Y, Tsukagoshi H, Yoshizumi M, Sasaki-Sakamoto T, et al. *MIP-1alpha level in nasopharyngeal aspirates at the first wheezing episode predicts recurrent wheezing*. *The Journal of allergy and clinical immunology* 2016; 137(3):774-781

18. Sejal S, Kristiina MM, Pelkonen AS, L Pekka M, Harry L, Merja K, et al. *Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction*. 2005; 171(7):722.

19. Teeratakulpisarn J, Pientong C, Ekalaksananan T, Ruangsiripiyakul H, Uppala R. *Rhinovirus infection in children hospitalized with acute bronchiolitis and its impact on subsequent wheezing or asthma: a comparison of etiologies*. *Asian Pacific journal of allergy and immunology* 2014; 32(3):226-234.

20. Nuolivirta K, Törmänen S, Teräsjärvi J, Vuononvirta J, Koponen P, Korppi M, et al. *Post-bronchiolitis wheezing is associated with toll-like receptor 9 rs187084 gene polymorphism*. 2016; 6:31165.

21. Korppi M, Nuolivirta K, Lauhkonen E, Holster A, Terasjarvi J, Vuononvirta J, et al. *IL-10 gene polymorphism is associated with preschool atopy and early-life recurrent wheezing after bronchiolitis in infancy*. *Pediatric pulmonology* 2017; 52(1):14-20.

22. Szulman GA, Freilij H, Behrends I, Gentile A, Mallol J. *Recurrent wheezing: prevalence and associated factors in infants from Buenos Aires City, Argentina*. *Boletin medico del Hospital Infantil de Mexico* 2017; 74(6):419-426.

23. Hon KL, Tsang KYC, Pong NHH, Leung TF. *Relevance of Cat and Dog Sensitization by Skin Prick Testing in Childhood Eczema and Asthma*. *Curr Pediatr Rev* 2017; 13(2):120-125.

24. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurborgsson F, et al. *Severe Respiratory Syncytial Virus Bronchiolitis in Infancy and Asthma and Allergy at Age 13*. *American journal of respiratory and critical care medicine* 2005; 171(2):137-141.

25. Ballardini N, Bergstrom A, Wahlgren CF, van Hage M, Hallner E, Kull I, et al. *IgE antibodies in relation to prevalence and multimorbidity of eczema, asthma, and rhinitis from birth to adolescence*. *Allergy* 2016; 71(3):342-349.

26. Pellegrini-Belinchon J, Lorente-Toledano F, Galindo-Villardon P, Gonzalez-Carvajal I, Martin-Martin J, Mallol J, et al. *Factors associated to recurrent wheezing in infants under one year of age in the province of Salamanca, Spain: Is intervention possible? A predictive model*. *Allergologia et immunopathologia* 2016; 44(5):393-399.

27. Shen R, Meng-Rong LI, Zhang LT, Zheng BJ. *Analysis of the correlation between the asthma predictive index and bronchiolitis at the first in infants and the forthcoming repeated wheezing*. 2017.
28. Dumas O, Hasegawa K, Mansbach JM, Sullivan AF, Piedra PA, Camargo CA, Jr. **Severe bronchiolitis profiles and risk of recurrent wheeze by age 3 years.** *The Journal of allergy and clinical immunology* 2018; 143 (4):1371-1379.

29. McBrien CN, Menzies-Gow A. **The Biology of Eosinophils and Their Role in Asthma.** *Front Med-Lausanne* 2017; 4.

30. Rossberg S, Gerhold K, Geske T, Zimmermann K, Menke G, Zaino M, et al. **Elevated blood eosinophils in early infancy are predictive of atopic dermatitis in children with risk for atopy.** *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology* 2016; 27(7):702-708.

31. Midulla F, Nicolai A, Ferrara M, Gentile F, Pierangeli A, Bonci E, et al. **Recurrent wheezing 36 months after bronchiolitis is associated with rhinovirus infections and blood eosinophilia.** *Acta paediatrica* 2014; 103(10):1094-1099.

32. Régnier SA, Jasper HJPIDJ. **Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae: systematic review and meta-analysis.** 2013; 32(8):820-826.

33. Aya T, Koichi H, Masatoki S, Toshiko S, Yoichi T, Ryo M, et al. **Clinical and epidemiologic factors related to subsequent wheezing after virus-induced lower respiratory tract infections in hospitalized pediatric patients younger than 3 years.** 2014; 173(7):959-966.

34. Valkonen H, Waris M, Ruohola A, Ruuskanen O, Heikkinen T. **Recurrent wheezing after respiratory syncytial virus or non-respiratory syncytial virus bronchiolitis in infancy: a 3-year follow-up.** *Allergy* 2009; 64(9):1359-1365.

35. Lukkarinen M, Lukkarinen H, Lehtinen P, Vuorinen T, Ruuskanen O, Jartti T. **Prednisolone reduces recurrent wheezing after first rhinovirus wheeze: a 7-year follow-up.** *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology* 2013; 24(3):237-243.

36. Tagarro A, Perez L, Quintero VM, Canete A. **Dexamethasone does not reduce length of hospitalization or recurrent wheezing 1 year after early bronchiolitis.** *Minerva pediatrica* 2014; 66(2):131-140.

37. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JOJAJRCCM. **Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis.** 2003; 168(6):633-639.

38. Chkhaidze I, Zirakishvili D, Shavshvishvili N, Bamabishvili NJPIAP. **Prognostic value of TH1/TH2 cytokines in infants with wheezing in a three year follow-up study.** 2016; 84(3):144.

**Tables**

Table 1 Scoring standard of bronchiolitis
### Table 2 Virus distribution in the 81 infants with bronchiolitis

| Viruses            | Total, n=81, no. (%) | RW⁻, n=63, no. (%) | RW⁺, n=18, no. (%) |
|--------------------|----------------------|--------------------|-------------------|
| RSV                | 36 (44.4)            | 29 (47.6)          | 7 (44.4)          |
| HRV                | 3 (3.7)              | 2 (3.2)            | 1 (5.6)           |
| Metapneumovirus    | 0 (0)                | 0 (0)              | 0 (0)             |
| HBoV               | 2 (2.5)              | 1 (1.6)            | 1 (5.6)           |
| Parainfluenza virus| 0 (0)                | 0 (0)              | 0 (0)             |
| Influenza virus    | 0 (0)                | 0 (0)              | 0 (0)             |
| Adenovirus         | 0 (0)                | 0 (0)              | 0 (0)             |
| One virus          | 41 (50.6)            | 32 (50.8)          | 9 (50.0)          |
| Two viruses        | 2 (2.5)              | 1 (1.6)            | 1 (5.6)           |
| Not detected       | 4 (4.9)              | 2 (3.2)            | 2 (11.1)          |

Note: RW⁻, patients with recurrent wheezing episodes; RW⁺, patients without recurrent wheezing episodes.

### Table 3 Comparison of baseline data between patients with and without recurrent wheezing episodes

| R (Times / min) | Wheezing      | Tri-retraction sign | Mental condition | Mental condition |
|-----------------|---------------|--------------------|------------------|------------------|
| <30             | No            | No                 | Normal           | Normal           |
| 31-45           | Only can be heard at the end of expiration by stethoscope | Only rib gap depression | Normal           | Normal           |
| 46-60           | Be heard during expiration with or without stethoscope | Trachea depression | Normal           | Normal           |
| >60             | Be heard during inspiration and expiration without stethoscope | Nasal flaring | Normal           | Normal           |

Irritability, drowsiness and decreased feeding
Table 4 Comparison of clinical characteristics between patients with and without recurrent wheezing episodes

| Factors                  | RW⁻, n=63(%) | RW⁺, n=18(%) | statistics | P    |
|--------------------------|--------------|--------------|------------|------|
| Sex (male)               | 41(65.1)     | 9(50.0)      | 1.348      | 0.280|
| Age (months)             | 5.20(1.03-19)| 3.97(1.30-9.83)| -0.704    | 0.481|
| premature birth          | 3(4.8)       | 0            | 0.890      | △1.000|
| LBW                      | 4(6.3)       | 0            | 1.202      | △0.570|
| Macrosomia               | 4(6.3)       | 2(11.1)      | 0.463      | △0.610|
| Feeding patterns         |              |              |            |      |
| breast feeding           | 35(55.6)     | 11(61.1)     | 0.176      | 0.675|
| Artificial feeding       | 7(11.1)      | 3(16.7)      | 0.051      | *0.821|
| mixed feeding            | 21(33.3)     | 4(22.2)      | 0.373      | *0.541|
| eczema                   | 33(52.4)     | 15(83.3)     | 4.348      | *0.037|
| Family history of asthma | 4(6.3)       | 2(11.1)      | 0.463      | △0.610|
| Exposure to smoking      | 29(46.0)     | 9(50.0)      | 0.089      | △0.795|
| Pet contact              | 1(1.6)       | 1(5.6)       | 0.915      | △0.397|

Note: RW⁺, patients with recurrent wheezing episodes; RW⁻, patients without recurrent wheezing episodes; LBW, low birth weight.

Data are expressed as % of positive cases, mean±SD or median (minimum-maximum), unless otherwise stated.

* Continuity correction.

△ Fisher exact test.

Table 5 Comparison of treatment and courses of disease between patients with and without recurrent wheezing episodes

| Factors                                | RW⁻, n=63(%) | RW⁺, n=18(%) | statistics | P    |
|----------------------------------------|--------------|--------------|------------|------|
| Fever                                  | 4(6.3)       | 3(16.7)      | 1.888      | △0.180|
| Feeding difficulty                      | 12(19.0)     | 5(27.8)      | 0.225      | *0.636|
| R>60 times / min                       | 4(6.3)       | 1(5.6)       | 0.000      | △1.000|
| Chest retractions                       | 3(4.8)       | 2(11.1)      | 0.974      | △0.307|
| Cyanosis                                | 2(3.2)       | 2(11.1)      | 1.878      | △0.212|
| moderate to severe condition           | 21(33.3)     | 11(61.1)     | 4.520      | 0.033|

Note: RW⁺, patients with recurrent wheezing episodes; RW⁻, patients without recurrent wheezing episodes; R: respiratory rate.

Data are expressed as % of positive cases, unless otherwise stated.

* Continuity correction.

△ Fisher exact test.
| Factors                        | RW-\(\oplus\), n=63(%) | RW+\(\oplus\), n=18(%) | statistics | \(P\) |
|-------------------------------|--------------------------|--------------------------|------------|-------|
| Oxygen inhalation             | 8(12.7)                  | 3(16.7)                  | 0.002      | *0.965|
| Systemic glucocorticoid       | 23(36.5)                 | 12(66.7)                 | 5.189      | 0.023 |
| Treatment                    |                          |                          |            |       |
| Hospital stay(d)              | 7.63±2.07                | 8.39±2.09                | 1.844      | 0.178 |
| Course of disease(d)          | 14.97(10,30)             | 16.28(11,30)             | -1.400     | 0.162 |

Note: RW\(\oplus\), patients with recurrent wheezing episodes; RW (-), patients without recurrent wheezing episodes.

Data are expressed as % of positive cases, mean±SD or median (minimum-maximum), unless otherwise stated.

* Continuity correction.

---

**Table 6** Comparison of laboratory examinations between patients with and without recurrent wheezing episodes

| Factors                        | RW-\(\oplus\), n=63(%) | RW+\(\oplus\), n=18(%) | statistics | \(P\) |
|-------------------------------|--------------------------|--------------------------|------------|-------|
| Blood cell count \((\times 10^9/L)\) |                          |                          |            |       |
| White blood cell              | 9.86±3.78                | 11.38±4.70               | 2.017      | 0.159 |
| Absolute lymphocyte count     | 6.05±2.84                | 7.15±2.95                | 2.061      | 0.155 |
| Absolute neutrophil count     | 2.87(0.24-8.87)          | 3.04(0.04-11.49)         | -0.358     | 0.720 |
| Eosinophil count              | 0.11(0.00-0.61)          | 0.09(0.00-0.59)          | -0.608     | 0.543 |
| Platelet count                | 441.41±129.12            | 454.83±109.95            | 0.161      | 0.690 |
| Humoral immunity(g/L)         |                          |                          |            |       |
| IgA                           | 0.18(0.01-1.03)          | 0.19(0.03-0.47)          | -0.657     | 0.511 |
| IgG                           | 4.64(2.44-10.59)         | 4.88(2.76-8.50)          | -0.853     | 0.394 |
| IgM                           | 0.65±0.33                | 0.67±0.34                | 0.062      | 0.804 |
| Cellular immunity             |                          |                          |            |       |
| CD3\(^+\)                     | 0.63±0.10                | 0.63±0.16                | 0.011      | 0.918 |
| CD4\(^+\)                     | 0.42±0.10                | 0.43±0.11                | 0.130      | 0.719 |
| CD8\(^+\)                     | 0.19±0.06                | 0.18±0.06                | 0.101      | 0.752 |
| CD4\(^+\)/CD8\(^+\)          | 2.52±1.19                | 2.67±1.26                | 0.217      | 0.643 |
| NK                            | 0.13(0.03-0.38)          | 0.12(0.05-0.35)          | -0.779     | 0.436 |
| CD19\(^+\)/CD23\(^+\)        | 0.12(0.02-0.31)          | 0.13(0.05-0.23)          | -0.087     | 0.931 |
| Serum total Ig E(IU/mL)       | 17.13(0.20-159.50)       | 38.71(1.90-367.00)       | -0.945     | 0.345 |
| Antigen-specific Ig E         |                          |                          |            |       |
| Milk protein                  | 4(6.3)                   | 3(16.7)                  | 1.888      | △0.180|
| Egg protein                   | 2(3.2)                   | 1(5.6)                   | 0.223      | △0.535|

Note: RW\(\oplus\), patients with recurrent wheezing episodes; RW (-), patients without recurrent wheezing episodes.

Data are expressed as % of positive cases, mean±SD or median (minimum-maximum), unless otherwise stated.

* Continuity correction.
Table 7 Comparison of serum level of cytokines between patients with and without recurrent wheezing episodes

| Cytokines | RW−, n=63 | RW+, n=18 | Statistics | P  |
|-----------|-----------|-----------|------------|----|
| IL-2      | 4.43(1.25-17.86) | 3.87(1.17-6.78) | -0.357 | 0.721 |
| TNF-α     | 1.18(0.00-4.57) | 0.78(0.00-2.97) | -0.410 | 0.159 |
| IL-4      | 25.02(6.86-47.18) | 20.81(7.83-39.7) | -1.609 | 0.108 |
| IL-5      | 7.52(2.41-16.06) | 6.50(1.78-11.55) | -1.021 | 0.307 |
| IL-13     | 3.01(0.75-6.42) | 2.52(1.22-4.20) | -1.392 | 0.164 |
| MIP-1α    | 14.25(7.68-32.24) | 12.98(7.61-18.85) | -0.825 | 0.409 |
| IL-25     | 60.11(19.53-124.22) | 48.46(15.99-108.74) | -1.833 | 0.067 |
| IL-33     | 30.84(12.69-77.18) | 27.93(7.75-50.12) | -0.643 | 0.520 |
| TSLP      | 10.34(3.98-18.42) | 9.01(3.27-14.16) | -1.259 | 0.208 |
| MMP-9     | 1575.09(23.71-9040.32) | 1436.08(116.00-6946.29) | -0.825 | 0.409 |
| TIMP-1    | 379.44(207.97-881.72) | 427.50(256.60-797.00) | -1.343 | 0.179 |

Note: RW+, patients with recurrent wheezing episodes; RW−, patients without recurrent wheezing episodes.

Data are expressed as median (minimum-maximum), unless otherwise stated.

Table 8 Logistic multivariable regression of the risk factors

| Predictive variable                  | P    | OR   | 95% CI       |
|--------------------------------------|------|------|--------------|
| Eczema                               | 0.023| 5.622| 1.3-24.9     |
| Systemic glucocorticoid treatment    | 0.053| 3.883| 1.0-15.4     |
| Moderate to severe condition         | 0.366| 1.927| 0.5-8.0      |
| IL-25                                | 0.470| 0.989| 1.0-1.0      |

Figures
Figure 1

Numbers of wheezing episodes over time in infants with bronchiolitis